Supplementary MaterialsSupplementary Data mmc1. the CB-SCs) into the patient’s blood circulation. This study is registered with ClinicalTrials.gov, “type”:”clinical-trial”,”attrs”:”text”:”NCT01350219″,”term_id”:”NCT01350219″NCT01350219. Findings Clinical data demonstrated that SCE therapy Rabbit polyclonal to STAT3 was well tolerated in all subjects. The percentage of na?ve CD4+ T cells was significantly increased at 26?weeks and maintained through the final follow-up at 56?weeks. The percentage of CD4+ central memory T cells (TCM) was markedly and constantly increased at 18?weeks. Both CD4+ effector memory T cells (TEM) and CD8+ TEM cells MS417 were considerably decreased at 18?weeks and 26?weeks respectively. Additional clinical data demonstrated the modulation of CCC chemokine receptor 7 (CCR7) expressions on na?ve T, TCM, and TEM cells. Following two treatments with SCE therapy, islet -cell function was improved and maintained in individuals with residual -cell function, but not in those without residual -cell function. Interpretation Current clinical data demonstrated the safety and efficacy of SCE therapy in immune modulation. SCE therapy provides lasting reversal of autoimmune memory that could improve islet -cell function in Caucasian subjects. Funding Obra Social La Caixa, Instituto de Salud Carlos III, Red de Investigacin Renal, European Union FEDER Funds, Principado de Asturias, FICYT, and Hackensack University Medical Center Foundation. and and em f /em ) show subjects 5 and 6 displayed some residual islet -cell function beyond MS417 10?years after diagnosis of T1D. After receiving SCE therapy, fasting C-peptide levels in Subject 5 initially decreased, but increased later at 40?weeks; fasting C-peptide levels in Subject 6 initially declined to 0.09?ng/ml at 26?weeks but improved to 0.21?ng/ml at 40?weeks. Their glucagon-stimulated C-peptide levels showed the similar tendencies as the fasting C-peptide levels. Table 2 Changes in C-peptide levels of the T1D subjects after treatment at 12?months. thead th align=”left” rowspan=”1″ colspan=”1″ Patient No. /th th colspan=”3″ align=”left” rowspan=”1″ Before treatment hr / /th th colspan=”3″ align=”left” rowspan=”1″ 12?m after SCE therapy hr / /th th align=”left” rowspan=”1″ colspan=”1″ Basal glycemia /th th align=”left” rowspan=”1″ colspan=”1″ Basal C-peptide /th th align=”left” rowspan=”1″ colspan=”1″ Post-glucagon C-peptide /th th align=”left” rowspan=”1″ colspan=”1″ Basal glycemia /th th MS417 align=”left” rowspan=”1″ colspan=”1″ Basal C-peptide /th th align=”left” rowspan=”1″ colspan=”1″ Post-glucagon C-Peptide /th /thead em Group A: T1D patients with residual islet cell function /em 11000.771.061750.841.312850.540.571490.440.831550.250.42800.360.4941411.052.181300.882.0151440.260.361780.170.2362180.230.271020.080.1 em Mean /em em 140.5 /em em 0.52 /em em 0.81 /em em 169 /em em 0.46 /em em 0.82 /em em (SD) /em em 46.8 /em em 0.34 MS417 /em em 0.73 /em em 61.4 /em em 0.33 /em em 0.73 /em br / br / em Group MS417 B: T1D patients with no residual islet cell function /em 7230 ?0.01 ?0.012320.010.018128 ?0.01 ?0.011350.010.019144 ?0.01 ?0.012440.010.0110198 ?0.01 ?0.011730.010.0111211 ?0.01 ?0.011820.010.0112111 ?0.010.041950.010.0113165 ?0.010.011740.010.021469 ?0.01 ?0.011230.010.01152430.020.061510.020.01 em Mean /em em 166.56 /em em ?0.01 /em em 0.037 /em em 178.78 /em em 0.01 /em em 0.01 /em em (SD) /em em 58.56 /em em 0.025 /em em 40.64 /em em 0.003 /em em 0.003 /em Open in a separate window Table 3 Changes in HbA1C levels and insulin doses of the T1D subjects after treatment at 12?months. thead th align=”left” rowspan=”1″ colspan=”1″ Patient No. /th th colspan=”2″ align=”left” rowspan=”1″ HbA1C hr / /th th colspan=”2″ align=”left” rowspan=”1″ Insulin dose (U/kg body weight) hr / /th th align=”left” rowspan=”1″ colspan=”1″ Before treatment /th th align=”left” rowspan=”1″ colspan=”1″ 12?m after SCE /th th align=”left” rowspan=”1″ colspan=”1″ Before treatment /th th align=”left” rowspan=”1″ colspan=”1″ 12?m after SCE /th /thead em Group A: T1D patients with residual islet cell function /em 17.17.40.280.2926.36.30.320.30399.30.520.5246.25.90.180.1957.88.90.40.369.290.610.6 em Mean /em em 7.6 /em em 7.8 /em em 0.38 /em em 0.37 /em em (SD) /em em 1.3 /em em 1.48 /em em 0.16 /em em 0.16 /em br / br / em Group B: T1D patients with no residual islet cell function /em 77.17.50.620.6386.260.720.7498.47.90.920.89109.18.40.790.8117.47.50.560.561210.19.20.580.57138.36.80.510.5146.56.60.710.72158.48.30.960.9 em Mean /em em 7.94 /em em 7.58 /em em 0.71 /em em 0.7 /em em (SD) /em em 1.26 /em em 1 /em em 0.16 /em em 0.15 /em Open in a separate window Additionally, no changes were observed in fasting C-peptide levels of severe long-standing Group B patients with no residual pancreatic islet cell function after receiving two SCE therapies (Table 2, Table 3). Their responses to SCE therapy were strikingly different from that reported in long-standing severe Chinese T1D subjects (Zhao et al., 2012, Zhao, 2012). The potential mechanisms underlying this difference need to be explored. 4.?Discussion Overcoming autoimmune memory is essential for eliminating autoimmunity in T1D and other autoimmune diseases. The current studies demonstrated the safety and feasibility of a two-treatment approach with SCE therapy, without significantly changing the numbers and ratios of different cell compartments in the subjects’ immune system. Both the percentage of CD4+ TEM and CD8+ TEM cells were substantially decreased in the peripheral blood of these Caucasian T1D subjects of European background after receiving SCE therapy, whereas the CD4+ TCM appeared to be favored by SCE therapy. Notably, the levels of CCR7 expression on na? ve T and TCM cells were markedly increased.